Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Hafnium Oxide-containing Nanoparticles NBTXR3 · NSC-158931

Other · developed by Nanobiotix

Phase 3 Most advanced trial
NBTX Developer
3 Registered trials

What is Hafnium Oxide-containing Nanoparticles NBTXR3?

NBTXR3 is a suspension of inert crystalline hafnium oxide nanoparticles injected into tumors. After radiation is applied, the particles emit electrons, generating free radicals that destroy cancer cells. It is studied in squamous cell carcinoma and non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NSC-158931, JNJ-90301900 (NBTXR3), NBTXR3
Drug type
Other
Pathways
free radical formation, electron emission under ionizing radiation
Therapy area
Oncology
Developer
Nanobiotix (NBTX)
Also in trials of
JNJ
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
3C4Z4KG52T

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04892173 Phase 3 Carcinoma, Squamous Cell Recruiting JNJ
NCT07224152 Phase 1/2 Locally-Advanced Non-Small Cell Lung Cancer Recruiting NBTX
NCT06667908 Phase 2 Carcinoma, Non-Small-Cell Lung Recruiting JNJ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLocally-Advanced Non-Small Cell Lung Cancer

More from Nanobiotix

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NBTX page.

Follow NBTX, the company behind Hafnium Oxide-containing Nanoparticles NBTXR3

See NBTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NBTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.